Lyra Therapeutics (LYRA) EBIT Margin (2021 - 2025)
Historic EBIT Margin for Lyra Therapeutics (LYRA) over the last 5 years, with Q3 2025 value amounting to 24948.0%.
- Lyra Therapeutics' EBIT Margin fell 185674900.0% to 24948.0% in Q3 2025 from the same period last year, while for Sep 2025 it was 3780.73%, marking a year-over-year increase of 106751500.0%. This contributed to the annual value of 4308.09% for FY2023, which is 1770500.0% down from last year.
- According to the latest figures from Q3 2025, Lyra Therapeutics' EBIT Margin is 24948.0%, which was down 185674900.0% from 4822.95% recorded in Q2 2025.
- Lyra Therapeutics' EBIT Margin's 5-year high stood at 860.98% during Q4 2024, with a 5-year trough of 137772.73% in Q4 2022.
- In the last 5 years, Lyra Therapeutics' EBIT Margin had a median value of 4822.95% in 2025 and averaged 18018.46%.
- In the last 5 years, Lyra Therapeutics' EBIT Margin plummeted by -1327402500bps in 2022 and then soared by 1264871100bps in 2023.
- Over the past 5 years, Lyra Therapeutics' EBIT Margin (Quarter) stood at 5032.47% in 2021, then plummeted by -2638bps to 137772.73% in 2022, then skyrocketed by 92bps to 11285.62% in 2023, then surged by 108bps to 860.98% in 2024, then plummeted by -2998bps to 24948.0% in 2025.
- Its last three reported values are 24948.0% in Q3 2025, 4822.95% for Q2 2025, and 4831.15% during Q1 2025.